NMO-IgG and AQP4 Peptide Can Induce Aggravation of EAMG and Immune-Mediated Muscle Weakness

Table 1

Aggravation of clinical severity and muscle strength in EAMG and naive mice by immunization with AQP4 peptide and NMO-IgG.

	EAMG control	EAMG + NMO-IgG	EAMG + AQP4 peptide	Naive + NMO-IgG	Naive + AQP4 peptide	Naive
Mean severity	0.624 ± 0.01	0.82 ± 0.01	1.5 ± 0.02	0.72 ± 0.01	0.63 ± 0.02	0
Gram force	242.8 ± 4.5	214.3 ± 4.5	219.4 ± 5.6	227.7 ± 8.9	219.6 ± 5.4	307.9 ± 7.4
Decrease in force (versus naive)	21.13%	30.40%	28.73%	26.03%	28.73%	0

versus EAMG control. versus naive.